Information updates


13 July 2020

Further to updates made in early 2020, the ASCIA Hereditary Angioedema (HAE) Position Paper has recently been updated in response to the New Zealand Minister of Health’s recent consent to the distribution of lanadelumab (published in the New Zealand Gazette on Tuesday 23 June 2020). 

The following statement has been included on page 12:

Lanadelumab is registered for prophylaxis of HAE attacks in New Zealand but is not yet funded. For those patients where it may be appropriate a NPPA application could be made to Pharmac. The recommended dose is 300mg SC every two weeks.

The updated ASCIA HAE Position Paper is available on the ASCIA website